Researchers led by Nobel Laureate David Baker at the University of Washington have developed artificial intelligence methods to design protein binders targeting peptide-MHC complexes, enabling precise recognition of cancer and viral antigens across diverse MHC alleles. Their platform rapidly produces low-immunogenicity proteins, with a specific binder demonstrating enhanced T cell-mediated killing of cancer cells in vitro. This AI-driven protein design advances scalable personalized immunotherapy approaches, overcoming challenges of MHC diversity and experimental limitations.